AbCellera Biologics Inc (ABCL) stock is lower by -56.69% since Friday, December 11, 2020 when AbCellera Biologics Inc began trading, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives ABCL stock a score of 30 out of a possible 100.
That rank is influenced by a long-term technical score of 0. ABCL's rank also includes a short-term technical score of 1. The fundamental score for ABCL is 90. In addition to the average rating from Wall Street analysts, ABCL stock has a mean target price of 53. This means analysts expect the stock to gain 107.76% over the next 12 months.
What's Happening with ABCL Stock Today
AbCellera Biologics Inc (ABCL) stock has fallen -4.04% while the S&P 500 is higher by 0.66% as of 10:47 AM on Friday, Mar 26. ABCL is lower by -$1.07 from the previous closing price of $26.58 on volume of 344,421 shares. Over the past year the S&P 500 has risen 7.42% while ABCL is lower by -56.69%. ABCL earned $0.02 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1403.66.
Click Here to get the full Stock Score Report on AbCellera Biologics Inc (ABCL) Stock.
